北京招聘

Role & Responsibility
Establishment of platforms of pharmacy and hospital management related science/association, Maintain good communication with experts and media companies，KOL professional visits and accurate information transmission, project planning and whole process management, etc.
Participate in organizing meetings, applying for projects, and hosting propaganda activities.
Work closely with internal and external stakeholders
药学、医院管理相关学/协会等平台的搭建，积极维护并开拓与专家团体和新闻媒体的关系， KOL的专业化拜访及信息精准传递，项目策划及全程管理等；
协助公司进行会议组织，项目申报和媒体宣传工作
密切配合公司内部团队和外部合作伙伴开展相关工作。
Requirement
Master degree in the major of Clinical medical, pharmaceutical, biomedical engineering or other relative majors;
Good English and Chinese both in oral and written, able to use as working language;
Strong execution and teamwork skills, Excellent communication and negotiation skills;
Experience in foreign enterprises, hospitals, government departments and industry associations in the pharmaceutical field is preferred;
Familiar with new drug clinical trials, registration regulations, GCP regulations is preferred.
临床医学、药学、生物医学工程等相关专业硕士研究生学历；
良好的写作、中英文语言表达能力；
较强的执行力和团队合作能力，优秀的沟通和谈判能力；
具有在跨国医药外企、医疗机构、国家部委机关事业单位以及医药相关行业协会（学会）等工作经验者优先，熟悉新药临床试验与注册法规、GCP法规、具有与国家政府部门对接经历者优先。

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.